Skip Navigation
Skip to contents

PHRP : Osong Public Health and Research Perspectives

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
2 "antiviral agents"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Articles
Effect of Paxlovid in COVID-19 treatment during the periods of SARS-CoV-2 Omicron BA.5 and BN.1 subvariant dominance in the Republic of Korea: a retrospective cohort study
Dong-Hwi Kim, Min-Gyu Yoo, Na-Young Kim, So Young Choi, Minjeong Jang, Misuk An, Se-Jin Jeong, Jungyeon Kim
Osong Public Health Res Perspect. 2024;15(2):137-149.   Published online March 28, 2024
DOI: https://doi.org/10.24171/j.phrp.2023.0230
  • 921 View
  • 43 Download
Graphical AbstractGraphical Abstract AbstractAbstract PDF
Objectives
This study was conducted to assess the efficacy of nirmatrelvir/ritonavir treatment in patients with coronavirus disease 2019 (COVID-19), particularly those aged 60 years and older. Using real-world data, the period during which the BN.1 Omicron variant was dominant was compared to the period dominated by the BA.5 variant. Methods: In this retrospective cohort study, data were collected regarding 2,665,281 patients infected with severe acute respiratory syndrome coronavirus 2 between July 24, 2022, and March 31, 2023. Propensity score matching was utilized to match patients who received nirmatrelvir/ ritonavir in a 1:4 ratio between BN.1 and BA.5 variant groups. Multivariable logistic regression analysis was employed to assess the effects of nirmatrelvir/ritonavir within these groups. Results: Compared to the prior period, the efficacy of nirmatrelvir/ritonavir did not significantly differ during the interval of Omicron BN.1 variant dominance in the Republic of Korea. Among patients treated with nirmatrelvir/ritonavir, a significantly lower risk of mortality was observed in the BN.1 group (odds ratio [OR], 0.698; 95% confidence interval [CI], 0.557–0.875) compared to the BA.5 group. However, this treatment did not significantly reduce the risk of severe or critical illness, including death, for those in the BN.1 group (OR, 0.856; 95% CI, 0.728–1.007). Conclusion: Nirmatrelvir/ritonavir has maintained its effectiveness against COVID-19, even with the emergence of the BN.1 Omicron subvariant. Consequently, we strongly recommend the administration of nirmatrelvir/ritonavir to patients exhibiting COVID-19-related symptoms, irrespective of the dominant Omicron variant or their vaccination status, to mitigate disease severity and decrease the risk of mortality.
Treatment with Sofosbuvir and Daclatasvir (with or without Ribavirin) Improves Patient Reported Outcomes in Hepatitis C
Lucas Pereira Jorge de Medeiros, Mario Barreto Correa Lima, Marcia Maria Amêndola Pires, Alessandra Mendonça Almeida Maciel, Renata Barboza Vianna Medeiros, Mariana Dermínio Donadel, Isabela Martins Becattini Pereira, Fábio Marchon Leão, Luiz Eduardo Amorim Correa Lima Pires, Helio Rzetelna, Carlos Eduardo Brandão-Mello
Osong Public Health Res Perspect. 2018;9(2):50-58.   Published online April 30, 2018
DOI: https://doi.org/10.24171/j.phrp.2018.9.2.03
  • 5,324 View
  • 40 Download
  • 4 Crossref
AbstractAbstract PDF
Objectives

To evaluate the impact of 3 treatment regimens upon health-related quality of life and work productivity using patient-reported outcomes (PROs) in chronic hepatitis C infected patients: sofosbuvir (SOF) + daclatasvir (DCV); SOF + DCV + ribavirin (RBV); SOF + simeprevir (SMV).

Methods

4 questionnaires were used to evaluate PROs before, during and after treatment: Short Form-36 (SF-36), Chronic Liver Disease Questionnaire (CLDQ) - hepatitis C virus (HCV), Work Productivity and Activity Index, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F).

Results

Of the global sample of 55 patients included in this study; SOF + DCV (n = 10); SOF + DCV + RBV (n = 29); SOF + SMV (n = 16) all had a statistically significant improvement in SF-36, CLDQ and FACIT-F scores during and post-treatment. No statistically significant differences in the PRO questionnaire values were observed between the distinct treatment regimens. The SOF and SMV patient groups presented higher mean PRO variations during and post-treatment, compared to the other groups: SF-36 functional capacity (16.1); SF-36 mental health (21.4); CLDQ activity (1.8); CLDQ emotional function (1.2); FACIT-F physical well-being (8.0); Total FACIT-F (21.6).

Conclusion

Treatment with SOF + DCV, with or without RBV, results in an improved PRO similar to treatment with SOF + SMV in chronic hepatitis C patients.

Citations

Citations to this article as recorded by  
  • Health-related quality of life in people receiving opioid agonist treatment and treatment for hepatitis C virus infection
    Olav Dalgard, Alain H. Litwin, Oren Shibolet, Jason Grebely, Ronald Nahass, Frederick L. Altice, Brian Conway, Edward J. Gane, Anne F. Luetkemeyer, Cheng-Yuan Peng, David Iser, Isaias Noel Gendrano, Michelle M. Kelly, Barbara A. Haber, Heather Platt, Amy
    Journal of Addictive Diseases.2023; 41(3): 213.     CrossRef
  • Impact of sofosbuvir and daclastavir on health-related quality of life in patients co-infected with hepatitis C and human immunodeficiency virus
    Evy Yunihastuti, Fhadilla Amelia, Arini Ika Hapsari, Bramantya Wicaksana, Veritea Natali, Alvina Widhani, Andri Sanityoso Sulaiman, Teguh Harjono Karjadi
    Health and Quality of Life Outcomes.2021;[Epub]     CrossRef
  • Health-related quality of life and fatigue in patients with chronic hepatitis C with therapy with direct-acting antivirals agents interferon-free
    Raíssa Neves Fagundes, Lincoln Eduardo Villela Vieira de Castro Ferreira, Fábio Heleno de Lima Pace, Yury E. Khudyakov
    PLOS ONE.2020; 15(8): e0237005.     CrossRef
  • Efficacy and safety of sofosbuvir-based pangenotypic direct-acting antiviral agents for chronic hepatitis C patients without genotype determination
    Juan Li, Dong-Bo Wu, Wei Jiang, Xue-Bin Chen, Gui-Bao Xiao, Yong-Hong Wang, Meng-Lan Wang, Ya-Chao Tao, En-Qiang Chen
    Medicine.2020; 99(43): e22726.     CrossRef

PHRP : Osong Public Health and Research Perspectives